December 2025 — Mission: Cure is pleased to announce a collaboration with Cibus Therapeutics and Greenstone Biosciences, two biotechnology companies working together developing next-generation treatments for pancreatic and gastrointestinal diseases. This partnership reflects Mission: Cure’s commitment to keeping the patient community informed about emerging science and supporting efforts to advance new therapies for chronic pancreatitis.
Why This Partnership Matters for Patients
People living with chronic pancreatitis face significant challenges, including severe pain, progressive tissue damage, and limited treatment options, most of which focus on symptoms rather than the underlying biology of disease. New therapies that address the root drivers of inflammation are urgently needed. CBT-101, an investigational therapy being co-developed by Cibus Therapeutics and Greenstone Biosciences, represents a novel approach to treating chronic pancreatitis.
About CBT-101: A New Small-Molecule Therapy
CBT-101 (developmental name) is an orally administered small-molecule therapy being designed to regulate key inflammatory pathways that become persistently overactive in chronic pancreatitis.
Small-molecule therapies are widely used in medicine and can enter cells easily, which lets them reach deep tissues (like the pancreas) and act directly on disease-driving processes.
CBT-101 aims to calm overactive inflammation, reduce tissue injury, and potentially slow or prevent fibrosis (scarring).
Early preclinical studies across multiple pancreatitis models have shown encouraging reductions in inflammation markers and tissue damage.
Development Stage and Timeline
To begin clinical testing, investigators must complete a series of safety, toxicology, and manufacturing studies and submit an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) or international equivalent to regulatory authorities.
An IND application includes:
- Results from laboratory and animal safety studies
- Information about drug manufacturing and quality
- A detailed plan for initial human trials
CBT-101 is currently in IND-enabling studies, the final set of preclinical steps required before clinical testing. Cibus Therapeutics and Greenstone Biosciences anticipate dosing the first study participant by Q3 2026, pending regulatory clearance.
Projected Timeline
2025-2026: Complete IND-enabling studies
2026: Submit IND application to the FDA
2026: Begin first-in-human Phase 1 trial (pending FDA or foreign equivalent clearance)
Phase 1 trials focus on safety, dosing, and understanding how the body processes the therapy. These early studies typically enroll a small number of participants. Mission: Cure will continue sharing updates as Cibus Therapeutics reaches these milestones.
Cibus Therapeutics on the Path Forward
“The complexity of chronic pancreatitis requires innovative therapies that can effectively address the multiple inflammatory pathways involved. CBT-101’s multi-targeted approach offers promise in tackling these challenges. We are committed to moving this therapy forward with the hope of delivering a treatment that not only eases symptoms but also changes the course of the disease for patients”
– Joseph Wu, Co-founder, Cibus Therapeutics and Greenstone Biosciences
“Chronic pancreatitis involves complex inflammatory processes that have, until now, lacked any treatment options. CBT-101 represents a novel approach by targeting multiple key pathways that drive this persistent inflammation. Cibus Therapeutics is excited to advance this therapy into clinical trials which will offer patients a meaningful new option to slow disease progression and improve quality of life”
– Honit Piplani, Director of Translational and Clinical Sciences, Cibus Therapeutics
About Cibus Therapeutics
Cibus Therapeutics, based in Palo Alto, California, develops targeted small-molecule therapies for inflammatory diseases, including chronic pancreatitis and inflammatory bowel disease. Their mission is to transform advanced scientific insights into safe, effective treatments that address urgent unmet needs in gastrointestinal health.
Frequently Asked Questions
CBT-101 is still in early development. If the IND application is approved and clinical trials progress successfully, several years of testing will be required before potential regulatory approval.
Eligibility criteria for the Phase 1 trial have not yet been announced. Mission: Cure will share this information once it becomes available from Cibus Therapeutics.
Visit Mission: Cure’s and Cibus Therapeutics website for resources, updates, and patient support programs.
About Mission: Cure
At Mission: Cure, we are dedicated to finding effective treatments and, ultimately, a cure for pancreatitis. Through patient education, research, and advocacy, we strive to improve the lives of those affected by this condition.
Get Updates in Your Inbox
Stay up-to-date on the latest Mission: Cure news and developments in pancreatitis care by signing up for our newsletter.